title: A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
abstract: Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies. Efficacy as monotherapy has been reported in patients with relapsed/refractory indolent and aggressive non-Hodgkin lymphoma (NHL) and in chronic lymphocytic leukemia (CLL) of B-cell origin. Improved outcomes have also been noted when obinutuzumab is added to chemotherapy in patients with B-cell NHL, and superiority over rituximab has been reported with combination therapy in patients with CLL. Ongoing research is focusing on developing options for chemotherapy-free treatment and on new combinations of obinutuzumab with novel targeted agents.
authors.affiliation: Department of Hematology, National Cancer Center Hospital, Tokyo, Japan. ktobinai@ncc.go.jp.
authors.forename: Kensei
authors.identifier: 0000-0002-7859-3227
authors.initials: K
authors.lastname: Tobinai
authors.affiliation: Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
authors.forename: Christian
authors.initials: C
authors.lastname: Klein
authors.affiliation: Oncology Lifecycle Management Department, Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Oya
authors.affiliation: Pharma Development Oncology, F. Hoffmann La-Roche Ltd, Basel, Switzerland.
authors.forename: Günter
authors.initials: G
authors.lastname: Fingerle-Rowson
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D000970:Antineoplastic Agents; C543332:obinutuzumab
keywords: Antibody-dependent cell-mediated cytotoxicity; B-cell lymphoma; CD20; Chronic lymphocytic leukemia; Glycoengineering; Monoclonal antibody; Non-Hodgkin lymphoma; Obinutuzumab; Oncology; Rituximab